Navigation Links
Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
Date:12/8/2012

immunotherapy.

The results after a follow-up of three to six months are:

  • The ORR was 83 percent
  • 38 of 40 patients continue on therapy without disease progression
  • 95 percent of all patients and 90 percent of patients with del17p had not progressed
  • There was a large and rapid reduction in lymph node and spleen sizes, with 84 percent of patients (26/31) experiencing more than a 50 percent decrease in lymph node size
  • Treatment was well tolerated overall, with Grade 3 or Grade 4 toxicities infrequent and transient in nature, including febrile neutropenia (fever with low white blood cell count), anemia, mucositis and pneumonia, in this clinical study

"We believe the updated findings from these two trials further affirm the possibilities of ibrutinib," said Bob Duggan, CEO and Chairman of the Board of Directors of Pharmacyclics. "We look forward to continuing our clinical development program for this therapy, and hope it can help us in achieving Pharmacyclics' mission of improving the quality and duration of life for patients with oncologic diseases."

About Ibrutinib
Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating B-cell apoptosis, cell adhesion, and lymphocyte migration and homing. Data are consistent with a mechanistic model whereby ibrutinib blocks BCR signaling, which drives cells into apoptosis and/or disrupts cell migration and adherence to tumor-protective microenvironments.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including CLL/SLL, relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and multiple myeloma. A comprehensive late stage P
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
7. Promising Data Presented on GenVec Malaria Program
8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Charm Sciences, Inc. is ... Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration ... Charm Sciences to monitor aflatoxin in grains utilizing ... ROSA FAST Aflatoxin Quantitative Test (solvent-based). , The ... uses Water Extraction Technology to extract aflatoxin from ...
(Date:5/21/2015)... N.J. (PRWEB) May 21, 2015 ... circulation audit and been admitted to BPA Worldwide ... BPA Worldwide will track audience data for Specialty ... coverage. , “By becoming a member of ... dedication to providing our clients with the most ...
(Date:5/21/2015)... -- Imagine being able to probe and ... others. Being able to read faces and enjoy genuine ... anticipate their thoughts and actions like never before. Use ... create unique abstract paintings and video, or, play a ... first-person-shooter as it creates action, dialog, and outcomes based ...
(Date:5/21/2015)... , May 20, 2015 Research and ... the addition of the "2015 Global Survey ... their offering. The primary goal of ... flow cytometry instruments and reagents. Key information the ... the selection of flow cytometers, predominantly used applications ...
Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2Specialty Pharmacy Times Joins BPA Worldwide 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Global Survey on Flow Cytometry Adoption Trends 2015 2
... ,Illinois Rising Stars, CHICAGO, Jan. 18 Brinks ... law firms in the United States, is,pleased to announce ... Lawyers" for 2008 in a survey conducted by Law ... "Rising Stars" in,Illinois., Meredith Martin Addy, chair of ...
... Jan. 18 Alba Therapeutics Corporation today,announced the ... and,Alliance Management. In this role, Ms. Perrow will ... program execution through,product approval and commercialization. Ms. Perrow ... management leadership team., "We are very pleased ...
... Jan. 18 In response to the,recent comments by ... lawsuits, CellCyte Genetics Corporation (the "Company") (OTC,Bulletin Board: CCYG) ... be shown to be so in a court of ... firm of Duane Morris LLP as its counsel and,will ...
Cached Biology Technology:Twenty-One Brinks Hofer Gilson & Lione Attorneys Named 2008 'Illinois Super Lawyers' 2Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management 2CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases 2CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases 3
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/6/2015)... AVIV, Israel , May 6, 2015 ... world,s most established helmet producer, announced today that they ... Smart Helmet, the world,s first bio-sensing cycling helmet and ... be released in two new colors in order to ... for the product. In addition, LifeBEAM and Lazer announced ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... 100 marine scientists, policy makers and members of industry ... observatories monitoring Europe,s seas, at the Marine Board-ESF ... will give reliable, long-term data to underpin science and ... energy, shipping, as well as tourism and recreation. ...
... Irvine, Calif., Sept. 16, 2010 UC Irvine researchers ... and reproduce actually evolve over time. The findings, reported in ... the long-held belief that sexual beings evolve the same way ... genetic research for new pharmaceuticals and other products. "This ...
... daily life of morbidly obese woman but also decreases ... can not lose weight or can not maintain weight ... valuable procedure to help morbidly obese individuals lose weight, ... profiles and lower mortality. Now, researchers have found another ...
Cached Biology News:Watch your seas: Marine scientists call for European marine observatory network 2UCI scientists decode genomes of sexually precocious fruit flies 2Significant weight-loss from surgery decreases risk for cardiovascular disease in women 2
... System is ideal for developing single and ... system contains the new, improved, and user ... user can design specific templates for commercial ... fully integrated graphing and data regression capabilities; ...
... Sweep- based acquision and ... evoked response type applications. Contains ... many flexible analysis functions including ... measurement plotting. Also includes many ...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: